FDA 510(k) Clearance Granted for Sequel’s twiist™ Automated Insulin Delivery System

Sequel Med Tech announced the FDA 510(k) clearance of the twiist™ Automated Insulin Delivery System, designed to improve insulin management for people with Type 1 diabetes. This system is designed to accurately measure insulin delivery with every dose and is suitable for patients aged 6 and up. The system integrates with continuous glucose monitoring (CGM) devices and offers personalized dosing capabilities. The twiist system adheres to FDA’s medical device interoperability standards and aims to enhance treatment customization and improve patient experience in diabetes management. 

For more details, read the full press release.